Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT04542135
PHASE2

Sulindac and Breast Density in Women at Risk of Developing Breast Cancer

Sponsor: Alison Stopeck

View on ClinicalTrials.gov

Summary

The primary objective of this study is to determine if sulindac at a dose of 150 mg twice a day for 12 months reduces breast density in postmenopausal women at elevated risk of breast cancer when compared to a placebo control.

Official title: Double-blind, Randomized Phase II Clinical Trial of Sulindac for Reducing Breast Density in Postmenopausal Women at Risk of Developing Breast Cancer

Key Details

Gender

FEMALE

Age Range

35 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

61

Start Date

2020-11-20

Completion Date

2025-05-19

Last Updated

2026-07-17

Healthy Volunteers

No

Conditions

Interventions

DRUG

Sulindac Pill

Randomized participants will receive either 150 mg oral sulindac twice daily.

DRUG

Placebo

placebo pills twice daily

Locations (2)

Cedars Sinai - Cancer

Los Angeles, California, United States

Stony Brook University Cancer Center

Stony Brook, New York, United States